Preventive oncology · 2026
Cancer prevention,
before the surgery room.
Asia carries nearly half the world’s cancer burden, and a large share of cancers are preventable or curable when caught early. We build evidence-based prevention programmes — hereditary risk testing, multi-cancer early detection, guideline screening and immune options — at China’s Class A hospitals, graded honestly.
~20M
New cancers / year
Worldwide, IARC GLOBOCAN 2022
IARC, 2022
49%
Asia's share
Half the world's cases, ~9.8M
IARC, 2022
~4.8M
China new cases
Nearly half of all Asia
IARC, 2022
30–50%
Preventable
Via modifiable risk factors
WHO
40–60
Golden window
Risk rising, disease still early
Incidence data
Top 5 >50%
China concentration
Lung · colorectal · stomach · breast · liver
China NCC
The case
The competitive edge
is in the screening room.
Most of medicine’s attention goes to treating cancer once it has arrived. But cancer rarely arrives suddenly — it builds over years, through a sequence of cellular steps, long before it is visible or symptomatic. That long runway is the opportunity prevention is built on.
The numbers make the case. On IARC GLOBOCAN 2022 data, there were about 20 million new cancers worldwide, and Asia accounted for roughly half — with China alone close to half of Asia’s total. In China five cancers (lung, colorectal, stomach, breast, liver) make up more than half of new cases, several of them screenable or tied to preventable infections.
We work the evidence-based levers: stratify inherited risk, detect early through guideline screening and multi-cancer early-detection testing, reduce modifiable risk, and discuss immune options like the WT1 vaccine honestly. This hub maps the whole toolkit and links to the deep dives — part of the same prevention-first philosophy as our longevity medicine programme.
The cluster
Six prevention pathways,
deep dives.
How cancer develops
The six stages from gene mutation to metastasis — and why each one opens a window for screening and risk-reduction before invasive cancer.
6 stages
Cancer statistics — China & Asia
IARC GLOBOCAN 2022 and China National Cancer Center data: global, Asia and China burden, top cancers by sex, and age-incidence trends.
2022 data
Multi-cancer early detection
Pan-cancer methylation blood testing — one draw flags a cancer signal across many cancers, including those with no routine screening.
$900–2.6k
TP53 genetic testing
Read your inherited cancer-defence baseline. Targeted, counselled testing for those with relevant family history.
$250–900
WT1 cancer vaccine
Therapeutic immunotherapy against the WT1 antigen — the NCI's top-ranked tumour antigen. Honestly graded: adjunct, not a preventive shot.
Case-by-case
Colonoscopy screening
The gold standard for colorectal cancer — China's second-commonest cancer — with same-day polyp removal that prevents cancer outright.
$300–900
The toolkit
Four layers of prevention.
Assess inherited risk
Personal and family history review, plus hereditary-cancer genetic testing (TP53, BRCA and panels) for those with relevant history — so high-risk people get intensified surveillance, not a one-size schedule.
Detect early
Guideline screening — colonoscopy, mammography, low-dose chest CT for eligible smokers, cervical screening — plus multi-cancer early-detection blood testing as a broad adjunct net.
Reduce modifiable risk
Smoking cessation, HPV and hepatitis B vaccination, alcohol and metabolic management. These prevent a large share of lung, liver, cervical and colorectal cancers outright.
Immune & advanced options
Where appropriate and evidence-based, immune approaches — therapeutic cancer vaccines such as WT1, and immune-cell support — discussed honestly with their real limits, not over-sold.
No programme eliminates cancer risk, and we don’t market unproven “anti-cancer” products. We assemble the evidence-based layers that fit your age, sex and risk profile — and tell you honestly which interventions add value and which don’t.
The pathway
From risk profile
to follow-through.
Risk profiling
We build your cancer-risk picture from age, sex, personal and family history, lifestyle and infection status (HPV, hepatitis B/C) — identifying which cancers actually warrant attention for you.
Programme design
A physician designs a tailored screening-and-prevention plan: which guideline screens, whether genetic testing or MCED adds value, and which risk-reduction steps matter most.
On-site screening
Screening is completed efficiently at a Class A hospital — often same-day endoscopy, imaging and labs — usually bundled with a longevity phenotyping visit or executive physical.
Bilingual report & plan
You receive a clinician-reviewed bilingual report with findings mapped to guidelines, a personalised screening calendar, and clear next steps for anything detected.
Follow-through
Any positive finding is worked up at the same hospital; risk-reduction and re-screening intervals are scheduled, with telehealth review and bilingual records throughout.
FAQ
Cancer prevention, answered.
- Can cancer actually be prevented?
- Partly, and meaningfully. The honest position: no programme eliminates cancer risk, but a large share of cancers are preventable or catchable early. The World Health Organization estimates that 30–50% of cancers are preventable through modifiable risk factors and that many more are curable when found early. Prevention works on three levels — reducing exposure (tobacco, alcohol, obesity, HPV and hepatitis B/C infection), detecting precancer and early-stage disease through screening, and stratifying inherited risk so high-risk people get intensified surveillance. We focus on these evidence-based levers, not on unproven 'anti-cancer' products.
- Why does cancer prevention matter so much in Asia and China?
- Scale. On IARC GLOBOCAN 2022 data, there were roughly 20 million new cancer cases worldwide, and Asia accounted for about 49% of them — as many as the rest of the world combined. China alone made up close to half of Asia's cases (~4.8 million). In China the burden concentrates in a handful of cancers — lung, colorectal, stomach, breast and liver together exceed half of all new cases — several of which are screenable or linked to preventable infections. That concentration is exactly what makes a structured prevention and early-detection programme high-yield.
- What is the 'golden window' for cancer screening?
- Incidence data show cancer risk is low before 40, rises sharply between 40 and 60, and climbs steeply after 60 — peaking around 70–85. The 40–60 band is often called the golden window because risk is rising but most disease is still early or pre-clinical, so screening and risk-reduction have the greatest impact on lifetime outcomes. Women's risk rises slightly earlier (driven by breast and gynaecological cancers in midlife); men's overtakes and exceeds women's after 60. We tailor the screening calendar to your age, sex and risk profile rather than applying one schedule to everyone.
- What does a cancer-prevention programme actually include?
- An evidence-based programme has four layers: (1) Risk assessment — personal and family history, and hereditary-cancer genetic testing (e.g. TP53, BRCA) for those with relevant history; (2) Early detection — guideline screening (colonoscopy, mammography, low-dose CT for eligible smokers, cervical screening) plus, as an adjunct, multi-cancer early-detection blood testing; (3) Risk reduction — smoking cessation, HPV and hepatitis B vaccination, metabolic and alcohol management; (4) Immune and advanced options where appropriate — discussed honestly, including therapeutic cancer vaccines such as WT1 in defined settings. We assemble the layers that fit you and skip the ones that don't.
- Is the WT1 cancer vaccine a way to 'prevent' cancer?
- This needs care. WT1 is a therapeutic cancer-vaccine target — strongly validated as an immunotherapy antigen (a US National Cancer Institute review of 75 tumour antigens ranked WT1 first). It is studied mainly as an adjunct for people who already have a WT1-expressing cancer, to reduce relapse. A Japanese dendritic-cell WT1 vaccine is also marketed for prevention in high-risk and sub-health groups, but robust evidence that it prevents cancer in healthy people is limited and investigational. We present it accurately — promising therapeutic immunotherapy, not a proven primary-prevention shot — on our dedicated WT1 page.
- How does cancer develop, and why does that matter for prevention?
- Cancer is a multi-step process, not a sudden event: a cell accumulates gene mutations (losing tumour-suppressors like P53, activating oncogenes like RAS), proliferates abnormally, forms a micro-tumour, recruits a blood supply (angiogenesis), then invades and metastasises while evading the immune system (e.g. via PD-L1). Because each step takes time, there is a long window before invasive cancer in which screening can catch precancer or early disease, and risk-reduction can interrupt the sequence. Understanding the stages is why early detection is so powerful — see our how-cancer-develops guide.
- Why come to China for cancer prevention and screening?
- China's Class A teaching hospitals run high-throughput health-management and oncology departments with same-day endoscopy, low-dose CT, advanced imaging and molecular testing, at a fraction of Western executive-health pricing — and with international departments for English-speaking coordination. For international patients this means a comprehensive risk-assessment and screening programme, with bilingual reporting, is accessible and affordable. Panda Touring Care partners only with NMPA-licensed Class A facilities and grades every option honestly.
Featured hospital
A Shanghai base for
screening and review.
Shanghai Ruidong Hospital · 上海瑞东医院
A private comprehensive hospital in Pudong with a dedicated health-screening centre, visiting oncology and internal-medicine consultants from the Ruijin Hospital Group, bilingual coordinators and direct insurance billing — a convenient base for executive checkups, risk review and specialist second opinions.
View hospital profileContinue exploring
How Cancer Develops
The six stages from gene mutation to metastasis — and the prevention windows each one opens.
Read the biologyCancer Statistics
China and Asia cancer data — burden, top cancers by sex, and age trends.
See the dataMulti-Cancer Early Detection
Pan-cancer methylation blood testing — a wider net across many cancers.
Read on MCEDTP53 Genetic Testing
Read your inherited cancer-defence baseline — the guardian-of-the-genome gene.
Read on TP53Health Checkup in China
The comprehensive executive physical that anchors a prevention programme.
See checkupsCancer Treatment in China
If cancer is found — the full oncology pathway at Class A hospitals.
See oncologyBuild your
prevention plan.
Tell us your age, family history and current screening. We’ll return a tailored cancer-prevention and screening plan from a partner Class A hospital — naming what adds value for your risk profile and what doesn’t.
This page is for general information only and is not medical advice. No screening or prevention programme can eliminate cancer risk; outcomes depend on individual risk, adherence and biological factors. We do not endorse unproven anti-cancer therapies or guarantee prevention.